JP2022541483A5 - - Google Patents

Info

Publication number
JP2022541483A5
JP2022541483A5 JP2022502556A JP2022502556A JP2022541483A5 JP 2022541483 A5 JP2022541483 A5 JP 2022541483A5 JP 2022502556 A JP2022502556 A JP 2022502556A JP 2022502556 A JP2022502556 A JP 2022502556A JP 2022541483 A5 JP2022541483 A5 JP 2022541483A5
Authority
JP
Japan
Prior art keywords
methyl
piperazine
oxo
carboxamide
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022502556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541483A (ja
JP7641944B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/070306 external-priority patent/WO2021013735A1/en
Publication of JP2022541483A publication Critical patent/JP2022541483A/ja
Publication of JP2022541483A5 publication Critical patent/JP2022541483A5/ja
Application granted granted Critical
Publication of JP7641944B2 publication Critical patent/JP7641944B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022502556A 2019-07-19 2020-07-17 Parp1阻害薬 Active JP7641944B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962876065P 2019-07-19 2019-07-19
US62/876,065 2019-07-19
PCT/EP2020/070306 WO2021013735A1 (en) 2019-07-19 2020-07-17 Parp1 inhibitors

Publications (3)

Publication Number Publication Date
JP2022541483A JP2022541483A (ja) 2022-09-26
JP2022541483A5 true JP2022541483A5 (cg-RX-API-DMAC7.html) 2023-07-26
JP7641944B2 JP7641944B2 (ja) 2025-03-07

Family

ID=71728735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502556A Active JP7641944B2 (ja) 2019-07-19 2020-07-17 Parp1阻害薬

Country Status (36)

Country Link
US (2) US11325906B2 (cg-RX-API-DMAC7.html)
EP (2) EP4529952A3 (cg-RX-API-DMAC7.html)
JP (1) JP7641944B2 (cg-RX-API-DMAC7.html)
KR (1) KR102929356B1 (cg-RX-API-DMAC7.html)
CN (1) CN114144413B (cg-RX-API-DMAC7.html)
AR (1) AR119424A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020318599B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000534A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145644A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000110A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001590A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220070A (cg-RX-API-DMAC7.html)
DK (1) DK3999506T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2022000006A (cg-RX-API-DMAC7.html)
EC (1) ECSP22012826A (cg-RX-API-DMAC7.html)
ES (1) ES3021859T3 (cg-RX-API-DMAC7.html)
FI (1) FI3999506T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250373T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071067T2 (cg-RX-API-DMAC7.html)
IL (1) IL289534B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20220008A1 (cg-RX-API-DMAC7.html)
LT (1) LT3999506T (cg-RX-API-DMAC7.html)
MA (1) MA57972B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022000711A (cg-RX-API-DMAC7.html)
MY (1) MY208549A (cg-RX-API-DMAC7.html)
PE (1) PE20221339A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550098A1 (cg-RX-API-DMAC7.html)
PL (1) PL3999506T3 (cg-RX-API-DMAC7.html)
PT (1) PT3999506T (cg-RX-API-DMAC7.html)
RS (1) RS66682B1 (cg-RX-API-DMAC7.html)
SI (1) SI3999506T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500146T1 (cg-RX-API-DMAC7.html)
TW (1) TWI837403B (cg-RX-API-DMAC7.html)
UA (1) UA129093C2 (cg-RX-API-DMAC7.html)
UY (1) UY38793A (cg-RX-API-DMAC7.html)
WO (1) WO2021013735A1 (cg-RX-API-DMAC7.html)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020023136A2 (pt) 2018-05-14 2021-02-09 Nuvation Bio Inc. compostos de alvo de receptor de hormônio nuclear anticâncer
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
IL301921A (en) 2020-10-09 2023-06-01 Daiichi Sankyo Co Ltd Combining an antibody-drug conjugate and a selective 1PARP inhibitor
EP4313991A1 (en) 2021-03-23 2024-02-07 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN116783181B (zh) * 2021-04-12 2026-01-30 上海瑛派药业有限公司 取代的稠合双环类化合物作为parp抑制剂及其应用
CN117177972A (zh) * 2021-04-19 2023-12-05 新特拉有限公司 Parp1抑制剂及其用途
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
WO2022222921A1 (zh) * 2021-04-22 2022-10-27 微境生物医药科技(上海)有限公司 含哌嗪结构的parp抑制剂、其制备方法及医药用途
CN116710433B (zh) * 2021-04-23 2026-05-05 康百达(四川)生物医药科技有限公司 一种选择性parp1抑制剂及其应用
CN116867783B (zh) * 2021-04-23 2026-08-07 康百达(四川)生物医药科技有限公司 吡啶衍生物及其在医药上的应用
CN116601148A (zh) * 2021-04-23 2023-08-15 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
CN117321051A (zh) * 2021-04-26 2023-12-29 重庆复尚源创医药技术有限公司 作为parp抑制剂的化合物
WO2022235585A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2022276986B2 (en) * 2021-05-18 2025-07-03 Onconic Therapeutics Inc. Parp inhibitor-resistant cancer therapeutic agent
AU2022280845A1 (en) * 2021-05-24 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
CN115403595A (zh) * 2021-05-27 2022-11-29 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
JP2024522736A (ja) * 2021-06-16 2024-06-21 リペア セラピューティクス インコーポレイテッド がん治療のためのparp阻害剤と組み合わせたatr阻害剤の使用
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
AU2022334408A1 (en) 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046158A1 (zh) * 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023051812A1 (zh) 2021-09-30 2023-04-06 海思科医药集团股份有限公司 含氮杂环衍生物parp抑制剂及其用途
WO2023051807A1 (zh) 2021-09-30 2023-04-06 海思科医药集团股份有限公司 双环衍生物parp抑制剂及其用途
WO2023051716A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
TWI876212B (zh) * 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
WO2023061406A1 (zh) * 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
US20250222116A1 (en) * 2021-10-22 2025-07-10 Xizang Haisco Pharmaceutical Co., Ltd. Parp-1 degradation agent and use thereof
AU2022392822B9 (en) * 2021-11-18 2026-08-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
CA3238572A1 (en) 2021-11-19 2023-05-25 Jing Zhang Selective parp1 inhibitor and application thereof
WO2023096915A1 (en) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Multicyclic compounds
CN118382624A (zh) * 2021-12-17 2024-07-23 凯复(苏州)生物医药有限公司 Parp抑制剂、包含其的药物组合物及其用途
AU2022422276B2 (en) * 2021-12-21 2025-12-11 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
WO2023122140A1 (en) * 2021-12-22 2023-06-29 Synnovation Therapeutics, Inc. Parp1 inhibitors
WO2023133413A1 (en) * 2022-01-07 2023-07-13 Slap Pharmaceuticals Llc Multicyclic compounds
US20250221987A1 (en) * 2022-01-13 2025-07-10 Acerand Therapeutics (Hong Kong) Limited Piperazino ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof
CN118434725B (zh) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
CA3246093A1 (en) * 2022-01-27 2023-08-03 Xinthera, Inc. PARP1 INHIBITORS AND THEIR USES
AU2023212785A1 (en) * 2022-01-28 2024-08-15 Xinthera, Inc. Parp1 inhibitors and uses thereof
CN116693501B (zh) * 2022-02-10 2025-12-19 康百达(四川)生物医药科技有限公司 一种喹唑啉酮衍生物及其在医药上的应用
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
WO2023165501A1 (zh) * 2022-03-01 2023-09-07 杭州领业医药科技有限公司 Azd5305的晶型及其制备方法和用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
CA3254948A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Polytherapy for the treatment of cancer
IL316019A (en) 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
AU2023250031A1 (en) * 2022-04-07 2024-11-14 Astrazeneca Ab Combination therapy for treating cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4514795A4 (en) * 2022-04-28 2025-12-31 Ningbo Newbay Tech Development Co Ltd COMPOUNDS USED AS PARP1 INHIBITORS
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
AU2023275808A1 (en) * 2022-05-25 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
US20250346573A1 (en) * 2022-06-02 2025-11-13 Chengdu Easton Biopharmaceuticals Co., Ltd. Azaquinolinone derivative, preparation method therefor and use thereof
KR20250023494A (ko) 2022-06-15 2025-02-18 아스트라제네카 아베 암 치료를 위한 병용 요법
CN115919859B (zh) * 2022-07-14 2024-01-05 四川海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用
TW202408509A (zh) * 2022-07-14 2024-03-01 大陸商西藏海思科製藥有限公司 雜芳基衍生物的藥物組合物及其在醫藥上的應用
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
CN119677736A (zh) * 2022-08-24 2025-03-21 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
WO2024041643A1 (zh) * 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
WO2024046420A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
TW202416977A (zh) * 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途
CN118139862A (zh) * 2022-09-30 2024-06-04 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
US20240174669A1 (en) * 2022-10-06 2024-05-30 Xinthera, Inc. Crystalline forms of a parp1 inhibitor
WO2024083218A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
CN120035592A (zh) * 2022-10-20 2025-05-23 成都赜灵生物医药科技有限公司 并杂环类氘代化合物及其用途
WO2024083201A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
US20260151378A1 (en) * 2022-10-21 2026-06-04 Shanghai Hansoh Biomedical Co., Ltd. Salt and crystal form of heterocyclic derivative inhibitor, and preparation method therefor and use thereof
WO2024097775A1 (en) * 2022-11-02 2024-05-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2024099386A1 (zh) * 2022-11-10 2024-05-16 正大天晴药业集团股份有限公司 稠合双环化合物
KR20250103773A (ko) 2022-11-23 2025-07-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법
CR20250267A (es) 2022-12-06 2026-01-14 Astrazeneca Ab Inhibidores de polq
AU2023412594A1 (en) * 2022-12-23 2025-07-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Parp1 inhibitors
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法
CN116396214B (zh) * 2023-03-06 2026-03-31 爱斯特(成都)生物制药股份有限公司 一种parp1抑制剂中间体的制备方法
US20240325384A1 (en) * 2023-03-31 2024-10-03 Astrazeneca Ab Dosing regimen
JP2026513665A (ja) 2023-03-31 2026-04-30 アストラゼネカ・アクチエボラーグ Azd5305の投与レジメント
JP2026515235A (ja) 2023-05-11 2026-05-14 アストラゼネカ・アクチエボラーグ 癌を治療するためのparp1阻害剤と選択的エストロゲン分解薬の併用
JP2026517228A (ja) 2023-05-17 2026-05-28 テサロ, インコーポレイテッド がんの治療におけるポリadpリボースポリメラーゼ(parp)阻害剤の新規使用
WO2024255782A1 (zh) 2023-06-14 2024-12-19 西藏海思科制药有限公司 双环衍生物parp抑制剂及其用途
GB2630970A (en) * 2023-06-15 2024-12-18 Duke Street Bio Ltd PARP1 inhibitor compounds
WO2024264072A2 (en) * 2023-06-23 2024-12-26 Stablix, Inc. Parp inhibitors
AU2024316921A1 (en) 2023-07-28 2026-02-05 Sunshine Lake Pharma Co., Ltd. Substituted nitrogen-containing bicyclic compound and use thereof
KR20260100685A (ko) 2023-10-23 2026-06-30 길리애드 사이언시즈, 인코포레이티드 Parp1 저해제 및 이의 용도
WO2025092973A1 (zh) * 2023-11-03 2025-05-08 成都赜灵生物医药科技有限公司 Parp1靶向化合物及其用途
AU2024394093A1 (en) 2023-12-05 2026-06-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
CN122555554A (zh) 2024-01-19 2026-08-11 阿斯利康(瑞典)有限公司 包含azd5305的药物组合物
CN120398887A (zh) * 2024-01-31 2025-08-01 西藏海思科制药有限公司 一种双环衍生物parp抑制剂的晶型及其制备方法和应用
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用
KR20250128449A (ko) 2024-02-20 2025-08-28 주식회사 종근당 Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
WO2025248119A1 (en) 2024-05-31 2025-12-04 Astrazeneca Ab 6-(cyclo)alkoxypurine derivatives useful as polq inhibitors
TW202608880A (zh) 2024-05-31 2026-03-01 瑞典商阿斯特捷利康公司 Polq抑制劑
WO2025261449A1 (zh) * 2024-06-19 2025-12-26 浙江扬厉医药技术有限公司 一种parp1抑制剂吡啶酰胺类化合物、中间体及其制备方法
KR20260019426A (ko) 2024-08-01 2026-02-10 주식회사 종근당 Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
CN118978529A (zh) * 2024-08-02 2024-11-19 上海信诺维生物医药有限公司 一类含吡啶的杂环化合物
GB2703160A (en) * 2024-12-09 2026-07-15 Duke Street Bio Ltd PARP1 Inhibitor Compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
NZ546991A (en) 2003-11-20 2010-01-29 Janssen Pharmaceutica Nv 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors
NZ546990A (en) * 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP4806353B2 (ja) 2003-12-05 2011-11-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ(adp−リボース)ポリメラーゼインヒビターとしての6−置換2−キノリノンおよび2−キノキサリノン
ES2565581T3 (es) 2003-12-10 2016-04-05 Janssen Pharmaceutica Nv 2-Quinolinonas/2-quinoxalinonas 6-(hetero)ciclohexilalquil sustituidas como inhibidores de poli(ADP-ribosa) polimerasa
KR20070057859A (ko) 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のsiRNAおよびその使用方法
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parpおよびtank阻害剤としてのキノリノン誘導体
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2389379A1 (en) * 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
EP2415767B1 (en) * 2009-03-27 2014-09-03 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) Polymerase (PARP) Inhibitors
US8541417B2 (en) * 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
JP2016522675A (ja) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
PT3312177T (pt) * 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
US10221156B2 (en) 2015-07-08 2019-03-05 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds

Similar Documents

Publication Publication Date Title
JP2023532257A5 (cg-RX-API-DMAC7.html)
HRP20250373T1 (hr) Inhibitori parp1
US10016426B2 (en) Pharmaceutical compositions for substituted quinazolinones
JP6021805B2 (ja) 腫瘍治療剤
JP2021102630A (ja) 血液学的悪性疾患および固形腫瘍の処置のためのidh1阻害剤
TWI351949B (en) Cftr inhibitor compounds and uses thereof
WO2024088273A1 (zh) 一种萘酰胺化合物治疗kras突变相关疾病的用途
JP2021121636A (ja) 悪性腫瘍の処置の方法
RU2006109769A (ru) Применение антагонистов crth2 в терапии
JP2005511722A6 (ja) Birb796bsの投与方法
TW201249800A (en) Method of treating cancer and bone cancer pain
JP2011509301A5 (cg-RX-API-DMAC7.html)
WO2012155806A1 (zh) 4-氨基喹唑啉衍生物及其应用
JP2010540666A5 (cg-RX-API-DMAC7.html)
JP2009513713A5 (cg-RX-API-DMAC7.html)
EP3181554B1 (en) Quinazoline derivative
JP2010531322A (ja) アントラニルアミドピリジンウレア及びベンズアミド誘導体の相乗組合せ
JP2011524362A5 (cg-RX-API-DMAC7.html)
JP2025510311A5 (cg-RX-API-DMAC7.html)
CN117412751A (zh) 用于预防或治疗肺纤维化的药物制剂
CN108349937A (zh) 二氨基吡啶衍生物
JP2005501834A5 (cg-RX-API-DMAC7.html)
JP7677646B2 (ja) 複製タンパク質a(rpa)-dna相互作用阻害剤
JP2025517442A5 (cg-RX-API-DMAC7.html)
TH2201000281A (th) ตัวยับยั้ง parp1